ReviewClinical proteomics2026
Proteomic and glycosylation biomarkers in rheumatoid arthritis: advancing early diagnosis and precision therapy.
Review in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint inflammation and damage. Early clinical diagnosis is crucial for effective intervention but presents significant challenges due to an initial asymptomatic inflammatory phase. MAIN BODY: Anti-citrullinated-protein antibodies (ACPA) and rheumatoid factor (RF) detection have been useful in early RA diagnosis, but their reliability is debatable as they are often non-specific. This has prompted a quest for alternative, more robust biomarkers. Researchers have turned to advanced proteomic and glycosylation analyses of biological fluids (e.g., synovial fluid, plasma and serum) and tissues using techniques such as MALDI-MS, Q-TOF, and SELDI-TOF. These approaches may offer a comprehensive approach to scrutinize a range of biomolecules as potential RA biomarkers, from citrullinated-proteins and peptides to novel potential protein biomarkers such as thymosin, macrophage-capping protein, calgranulins, and serum amyloid-A. Further, proteomics-based approaches have the ability to specifically monitor changes in the RA proteome (e.g., glycosylated VCAM1/SEMA4D proteins and GFAP/A1BG auto-antibodies) to unearth potential diagnostic and prognostic candidates. Disease monitoring in response to anti-rheumatic drugs using treatment-responsive markers, such as S100A8/A9 heterocomplex and leucine-rich alpha-2 glycoprotein, is another application of proteomics-based technologies.
conclusionIn view of the significance of prediction, early diagnosis and monitoring of RA symptomatology, this review discusses the potential utilities of proteinaceous species as proteomics-based biomarkers that may provide insights into disease mechanisms and offer potential avenues for personalized therapeutic interventions to revolutionize RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.